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incidence of HCC in China and Africa reflects the elevated prevalence of chronic HBV infection. 2, 5 However, HCC in the United States, Western Europe, and Japan more commonly arises in the context of liver injury due to chronic hepatitis C virus (HCV). 3, 6 Other important risk factors implicated in the etiology of HCC include aflatoxin B1 exposure, alcoholic cirrhosis, diabetes, obesity, and nonalcoholic steatohepatitis (NASH). The risk of HCC was found to significantly increase with an alcohol exposure of > 80 g ethanol per day compared with no exposure, and was elevated 54-fold in the presence of both viral infection and alcohol exposure. 7, 8 Patients with diabetes had a significantly higher incidence rate (2.39 vs 0.87 per 10,000 person-years, respectively, p < 0.0001) compared with patients without diabetes in a study of 824,263 patients. 9 In a large prospective study, a high body mass index (BMI) of 35.0-39.9 was associated with a 4.5-fold increased risk of HCC. 10 Moreover, synergistic interaction among alcohol exposure, diabetes, and obesity might further increase the risk of HCC. 8 The relationship between tobacco use and risk of HCC is presently unclear; however, a casecontrolled study demonstrated a fivefold increase in the risk of HCC after an exposure of 20 pack-years.
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Given that chronic HBV and HCV infections are the major risk factors for HCC, prevention of these infections would have a huge impact on the worldwide incidence of HCC. Rigorous HBV vaccination measures have been highly successful in preventing both neonatally acquired HBV and adult HBV infections and consequently, in reducing the risk of HCC.
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In addition to vaccinations, some evidence indicates that antiviral therapies may play an important role in preventing complications from chronic HBV infection and progression to HCC. In a placebo-controlled study of 651 patients with chronic HBV infection, antiviral therapy with lamivudine reduced the incidence of HCC by 51% compared with placebo (3.9% vs 7.4%; hazard ratio [HR] ¼ 0.49; p ¼ 0.047). 13 In the case of HCV, where no vaccine is available, preventative strategies include disrupting transmission through good clinical practices, reducing high-risk behaviors through public education, and managing chronic infections with combined antiviral therapy including novel agents such as boceprevir or telapravir. 14 Other, modifiable risk factors, such as alcohol use, diabetes, obesity, and smoking, will likely get more attention once preventative strategies against viral hepatitis are well implemented. Prior to discussing diagnostic and treatment approaches for HCC, the implications of the heterogeneity of HCC and underlying liver disease must be underscored. Although it is known that up to 70% of HCC develops in the setting of chronic liver disease, 15, 16 the molecular evolution of HCC is a complex, multistep process that is still not completely understood. However, two major mechanisms seem to be the most important: the development of liver cirrhosis and the alteration of oncogenes and tumor suppressor genes leading to aberrant cell signaling pathways. Targeting these signaling pathways represents a rationale for modern systemic therapy of HCC and is discussed later in this supplement. Due to the complex nature of HCC and its association with liver dysfunction, the management of this malignancy requires close collaboration among a multidisciplinary team of hepatologists/gastroenterologists, pathologists, radiologists, surgeons, and oncologists. Timely selection of a therapeutic intervention and referral to the appropriate specialist within the multidisciplinary team is critical to deliver optimal patient care in this disease.
Surveillance and Diagnosis
Screening and surveillance are highly important for early detection of HCC in patients considered to be at risk, such as Asian HBV carriers, Blacks with hepatitis B, HBV carriers with family history of HCC, patients with cirrhosis and chronic HBV or HCV, genetic susceptibility (hemochromatosis, α 1-antitrypsin deficiency), or cirrhosis of other etiology.
17
Hepatologists/gastroenterologists at the forefront of managing patients with chronic liver diseases play a critical role in the implementation of surveillance programs. The combination of ultrasound and α-fetoprotein (AFP) evaluation has been shown to reduce mortality by 37% in patients with HBV, 18 supporting the need for HCC surveillance. However, in a pooled analysis in patients with early HCC, ultrasound was shown to have only 63% sensitivity. 19 Cost-effectiveness and cost-benefit analyses have indicated that the surveillance strategy of ultrasound and AFP appears to be the best, 20, 21 and a recent prospective study showed that ultrasound and AFP are complementary, with a sensitivity of 90% and specificity of 83%.
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The practice guidelines of the American Association for Liver Diseases (AASLD) recommend ultrasound alone at 6-month intervals for HCC surveillance, 17 but the National Comprehensive Cancer Network (NCCN) and other societies recommend the combination of ultrasound and AFP. 23 There is a need to identify novel biomarkers, either alone or to complement ultrasonography, to improve the performance characteristics for the detection of early HCC. When suspicious nodules are identified, the current diagnostic algorithm (►Fig. 1) proposed by the AASLD recommends that liver nodules < 1 cm be observed with ultrasound every 3 months until stability or growth of the lesion is established. 17 For lesions > 1 cm, characteristic intense arterial uptake followed by contrast washout in the venous-delayed phases should be detected with 4-phase multidetector computer tomography (MDCT) or dynamic contrast-enhanced magnetic resonance imaging (MRI). With the improved accuracy and sensitivity of imaging modalities, liver biopsy is currently not indicated for the diagnosis of HCC in a cirrhotic liver, and is even considered controversial. Although specificity of liver biopsy is almost 100%, sensitivity varies and depends on the tumor size and location and the size of the needle used for biopsy. Additionally, there is a small risk (2.7%) of tumor seeding after liver biopsy. 24 According to the AASLD guidelines, biopsy is warranted only in instances where neither MDCT nor MRI shows characteristics of HCC, and is most useful in hypovascular tumors and in small nodules < 1 cm. 17 Histologic confirmation of HCC requires positive results for at least two of the following three immunostains: glypican 3, heat shock protein 70, and glutamine synthetase. 
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Liver transplantation offers the best survival benefit for patients with early-stage disease by reducing the potential for recurrence through the elimination of undetectable liver lesions and underlying liver disease. The above-mentioned Milan criteria are globally used to select patients for liver transplantation; patients receiving a transplant according to this criteria have a 4-year overall survival (OS) of 75% and only an 8% risk of recurrence. 51 To expand listing criteria for patients with HCC, the University of San Francisco (UCSF) developed modified criteria in which patients with a solitary lesion of 6.5 cm in diameter or 3 lesions 4.5 cm with a total combined diameter of 8 cm are eligible for transplant. 52 However, the UCSF criteria have not been formally adopted by United Network for Organ Sharing (UNOS) due to the scarcity of donor livers. The UNOS primarily uses the Model for End-Stage Liver Disease (MELD) criteria, a composite score of liver function parameters that assesses the risk of life-threatening liver failure, to allocate available livers for transplantation. Because MELD does not consider mortality risk from HCC, additional points are given for presence of HCC to prioritize for transplantation. The long waiting time between listing and transplantation has also led to strategies for increasing the donor pool, such as using living donors and split liver transplantation. 17, 53 In addition, withdrawal from the waiting list due to disease progression might be reduced by use of a locoregional "bridge therapy," such as TACE or ablation. [54] [55] [56] [57] There is evidence that response to preoperative TACE to "downstage" HCC led to better long-term survival following transplantation, particularly in patients that fit the Milan criteria. 58, 59 Importantly, the number of donors available for liver transplant has plateaued over the past 10 years to 1500/year for patients with HCC, 60 while the number of patients with HCC has grown significantly to over 28,000. 
Intermediate-Stage HCC
Patients with large multimodal tumors, preserved liver function, and no vascular invasion or extrahepatic spread who are ineligible for radical surgical therapies or percutaneous ablation are usually treated with TACE. 17 Transarterial chemoembolization involves the intra-arterial injection of a cytotoxic agent (doxorubicin, cisplatin, or mitomycin), with or without lipiodol, plus an embolic agent into the hepatic artery that supplies the tumor. In a meta-analysis of seven studies, TACE demonstrated a significant improvement in 2-year survival (odds ratio ¼ 0.53; p ¼ 0.017) compared with best supportive care. 67 However, patient selection appears to be critical for achieving a survival advantage with this method. In the positive Barcelona study, a 2-year OS of 63% and objective responses of 35% were reported for patients treated with TACE, but 70% of them had compensated liver disease (Child-Pugh A) with no vascular invasion or extrahepatic spread. 68 Another study found that among patients treated with TACE, those with unilobular portal vein invasion and tumors > 5 cm did not show a survival benefit. 69 In both of these studies, the long-term outcomes were unsatisfactory with a 3-year OS of only 30%, highlighting the need for improved strategies to optimize outcomes. To further improve outcomes and tolerability of TACE, a new drug delivery system has been developed using doxorubicin-eluting beads (DEB), which provides embolization and releases the cytotoxic agent in a controlled fashion (DEB-TACE). 70 Encouraging tolerability and response rates of 70-85% have been reported with this technique.
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However Better understanding of the molecular pathogenesis of HCC has led to recognition of the importance of angiogenesis for tumor development, growth, and progression, thus making angiogenesis an attractive target. Proangiogenic factors, such as vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) and their receptors, have been shown to have important roles in facilitating HCC angiogenesis. Sorafenib, a multitargeted tyrosine kinase inhibitor that blocks several key modulators of angiogenesis, including VEGFR2, PDGFR, Raf-1 and B-Raf receptors, is the first drug to show a survival benefit in patients with advanced HCC and represents a paradigm shift in the systemic treatment of this disease. Its efficacy was proven in two large, randomized, placebo-controlled clinical trials, which mainly included patients with advanced HCC and Child-Pugh A liver disease. 81, 82 The inferior magnitude of benefit of the Asia-Pacific study compared with the SHARP study may be partly attributable to differences in patient characteristics, disease heterogeneity, and etiopathology between the trials. Seventy-five percent of patients in the Asia-Pacific study exhibited hepatitis B etiology, compared with only 19% in the SHARP study. In addition, patients enrolled in the Asia-Pacific study had a worse performance status and more advanced stage disease in general than those in the SHARP study. In both trials, hand-and-foot skin reaction, diarrhea, rash, and fatigue were among the most commonly reported adverse effects.
In both of these studies of sorafenib in the treatment of HCC, the improvements in OS and TTP were not accompanied by benefit in terms of objective response, highlighting the lack of utility of conventional RECIST criteria for evaluation of tumor response to molecular targeted therapy. Recently developed modified RECIST (mRECIST) criteria propose the assessment of response to molecular targeted therapy (or locoregional therapy) in patients with HCC based on measurement of viable tumor with arterial enhancement on a computed tomography scan, not anatomical tumor response. 83 Although the mRECIST is utilized in the assessment of response in systemic therapies, it needs further validation. When response to sorafenib was assessed according to both mRECIST and conventional RECIST criteria in patients with advanced HCC, a higher rate of objective responses was identified with mRECIST (23% vs 2%), and patients who achieved a response according to mRECIST had a longer OS than nonresponding patients (18 months vs 8 months, p ¼ 0.013).
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Although it is indisputable that sorafenib represents a major advancement in the management of unresectable advanced-stage HCC, several unanswered questions and unmet needs still remain. The clinical benefit with sorafenib appears to be modest and short-lived, even in patients with preserved liver function. In addition, there is currently no reliable predictive biomarker for monitoring response or indicating treatment resistance. The registrational trials also did not provide data on the safety and efficacy of sorafenib in patients with compromised liver function. However, the postapproval observational GIDEON study (Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment with Sorafenib) showed that sorafenib 400 mg twice daily could be safely prescribed to selected Child-Pugh B patients. 85 Sorafenib is also being examined in the neoadjuvant and adjuvant settings in combination with locoregional therapies. 
Conclusion
Recent years have witnessed significant changes in the management of HCC. Multidisciplinary approaches to management of this disease and diagnostic and treatment algorithms that accommodate the unique aspects of HCC, including its pathobiology, heterogeneity, and underlying liver impairment, have been developed. The introduction of sorafenib therapy has validated the targeted approach to this disease and represents a major paradigm shift in the treatment of advanced HCC, leading to the identification of other potential targets and the development of new targeted agents in HCC, which are discussed in the next article.
